Navigation Links
Trails to detect effective breast cancer drugs that reduces recurrences

A quest for new drug has started to determine and help patients to have a recurrence free survival after breast cancer surgery. The chemotherapy drugs docetaxel (Taxotere) and vinorelbine (Navelbine) are tested to analyze the outcomes.//

It was previously reported by the Finnish researchers that patients who received infusions of trastuzumab (Herceptin) were less likely to get recurrences in the New England Journal of Medicine.

Dr. Heikki Joensuu, corresponding author and a physician at Helsinki University Central Hospital said that the breast cancer recurrence reduced by 42% during the first 3 years of follow-up among women treated with docetaxel when compared to those who received vinorelbine.

But on the other hand it was found that docetaxel was associated with more adverse effects such as allergic reactions, swelling and fever.

Joensuu and his colleagues conducted a study in more than a thousand women with breast cancer.

They gave them three cycles of either docetaxel or vinorelbine, followed by three cycles of other cancer drugs.

Then, a subgroup of 232 women was identified whose tumors had an amplified HER2/neu gene. This gene is known to be associated with cancers that grow and spread aggressively.

They were also assigned either to receive nine weeks of infusions of Herceptin or a placebo. By doing this the researchers were able to identify the best regime for recurrence-free survival.

The result of the study was that patients who received Herceptin had 58 % fewer cancer recurrences during the three-year follow-up than those who didn't get the drug. Previous studies also show that adjuvant trastuzumab [Herceptin] if taken for a course of one year reduces the rate of breast cancer recurrence by 50 % in women having HER2-positive breast cancer.

But it is not clearly understood about the optimal duration of the drug usage. Dr. Mark Pegram, director of the women's cancer pr ogram at the Jonsson Cancer Center at the David Geffen School of Medicine at UCLA said that if it is the short nine week regime that turns out to be ideal then it is great news. But still this question remains to be confirmed.


'"/>




Related medicine news :

1. Clinical Renal Trails Do Not Have Sufficient Women Participants
2. Clinicians Participating In the Pharmaceutical-Sponsored Trails Tend To Prescribe Their Drugs
3. CDC To Conduct Pre-clinical Trails Of BioDiems Intranasal Bird Flu Vaccine
4. Vitamin B12 can help in detecting cancers
5. “Brain fingerprinting”- The new lie detectr
6. Ductal lavage may detect early breast cancer
7. Better prostate cancer detection
8. Early detection of prostate cancer
9. Early detection of heart attack
10. Cytobrush to detect oral cancer
11. New device for detecting artery blockages
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
(Date:6/24/2016)... ... 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ), ... official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the practice, ... says the decision to support the pageant in an official capacity is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Southern Illinois ... are co-chairs for the Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy ... Gateway Convention Center in Collinsville. , They expect to treat approximately ...
(Date:6/24/2016)... Austin, TX (PRWEB) , ... June 24, 2016 , ... ... laude graduate, joins Evans Dermatology in the South Lamar location as of July 13, ... Texas Southwestern Medical School. As a medical student, she regularly volunteered at the Agape ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: